1. Home
  2. ALLR vs CFND Comparison

ALLR vs CFND Comparison

Compare ALLR & CFND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$0.79

Market Cap

19.3M

Sector

Health Care

ML Signal

HOLD

Logo C1 Fund Inc.

CFND

C1 Fund Inc.

HOLD

Current Price

$1.84

Market Cap

20.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLR
CFND
Founded
2004
N/A
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.3M
20.4M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
ALLR
CFND
Price
$0.79
$1.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 136.5K
31.7K
Earning Date
11-13-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $320,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.77
$1.85
52 Week High
$1.84
$5.66

Technical Indicators

Market Signals
Indicator
ALLR
CFND
Relative Strength Index (RSI) 38.05 20.58
Support Level N/A N/A
Resistance Level $1.45 $3.48
Average True Range (ATR) 0.09 0.15
MACD -0.01 -0.03
Stochastic Oscillator 3.70 1.49

Price Performance

Historical Comparison
ALLR
CFND

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

About CFND C1 Fund Inc.

C1 Fund Inc is a non-diversified, closed-end management investment company. The Adviser provides day-to-day investment management services to the Company, which is classified as non-diversified under the Investment Company Act. The Company's investment objective is to maximize its portfolio's total return by principally investing in privately held equity and equity-linked securities of digital asset services and technology companies. Its investments in equity securities include common and preferred shares, securities convertible into common shares, warrants and rights to subscribe to or purchase common shares, and common shares carrying a warrant or right.

Share on Social Networks: